Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL-3D ramucirumab + erlotinib in treatment-naive EGFR-mutant, high PD-L1 NSCLC
jRCTs051220149Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Mar 2023; status: active, not recruiting.
02
Drugs
ramucirumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051220149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220149.